Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Low prevalence of community-acquired influenza coinfections among COVID-19 patients in Al-Madinah, Saudi Arabia: A retrospective cohort study

Sari T. Alhoufie, Khalid O. Alfarouk, Hatim M. Makhdoom, Nadir A. Ibrahim

Medical Laboratories Technology Department, College of Applied Medical Sciences, Taibah University, Al-Madinah Al-Munwarah, Saudi Arabia

Zamzam Research Center, Zamzam University College, Khartoum, Sudan

Alfarouk Biomedical Research LLC, 33617 Temple Terrace, Florida, USA

Article history:
Received 19 January 2022
Received in revised form 20 May 2022
Accepted 5 June 2022

Keywords:
SARS-CoV-2
Influenza A
Influenza B
Parainfluenza-2
Community-acquired respiratory infections

Abstract

Background: Coinfections with respiratory viruses among SARS CoV-2 patients have been reported by several studies during the current COVID-19 pandemic. Most of these studies designated these coinfections as being hospital-acquired infections; however, there is inadequate knowledge about community-acquired respiratory coinfections among SARS CoV-2 patients.

Methods: In this retrospective cohort study, we investigated the seroprevalence of influenza A, influenza B, and parainfluenza-2 among newly hospitalized patients with confirmed COVID-19 infections (n = 163). The study was conducted during the early phase of the COVID-19 pandemic in Saudi Arabia (from April to October 2020). The patients’ serum samples were subjected to commercial immunoglobulin M (IgM) antibody tests against the three aforementioned viruses.

Results: Seropositivity for influenza A and B and parainfluenza-2 occurred only in 4.2% (7/163) of COVID-19 patients, indicating simultaneous acute infections of these three viruses with SARS CoV-2 infection. All coinfection cases were mild and misdiagnosed during the care period in the hospital.

Conclusion: This study highlights the low prevalence of community-acquired respiratory infections among COVID-19 patients in the current pandemic and we discussed the possible factors for this finding. During newly emerging epidemics or pandemics, considering other respiratory viruses circulating in the community is essential to avoid their misdiagnosis and account for their possible negative effects on pandemic disease management and prognosis.

© 2022 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged, enveloped RNA virus that belongs to the β-coronavirus family [1]. The virus exhibits the ability to be transmitted via different modes such as direct/indirect contact as well as droplet and airborne routes, making it highly contagious [2]. SARS CoV-2 can cause illnesses ranging from mild respiratory infection to severe pneumonia and acute respiratory distress syndrome (ARDS). Fever, dry cough, and fatigue are the most common symptoms, while loss of taste or smell, headache, diarrhea, nasal congestion, and red eyes are less common [3–5].

SARS-CoV-2 has become a significant challenge and concern for global public health since its emergence in Wuhan, China, in December 2019 [6]. The first case of COVID-19 infection in Saudi Arabia was reported on March 2, 2020. Since then, the number of cases has exceeded 632,736, with 8912 deaths as of January 19, 2022 [7].

Beyond SARS-CoV-2 pathogenesis, the incidence of infections of other respiratory viruses along with COVID-19 has been observed in different studies worldwide. The impact of viral coinfection on COVID-19 patients is not fully understood but respiratory viruses, in general, can damage the airway epithelium, decrease mucociliary clearance, and trigger immune system disorders [8–10]. Therefore, coinfections have clinical significance, being related to a prolonged hospital stay with a higher required level of care and impacting the disease prognosis by possibly leading to ARDS and other complications [11].
Coinfections of circulating respiratory viruses have also been reported in previous respiratory virus outbreaks. For instance, during the Middle East respiratory syndrome coronavirus (MERS-CoV) epidemic in Saudi Arabia in 2017, Alfaraj and colleagues reported influenza virus coinfections among MERS-CoV patients [12]. During the current COVID-19 pandemic, several studies have reported coinfections of respiratory viruses among COVID-19 patients. Early observations (February 2020) by Wang and colleagues in Wuhan, China, revealed that coinfections occurred in 5.8% of COVID-19 patients and that the median age of the patients was 51 years [13]. Another study in the United States found that 20.7% of COVID-19-positive patients were coinfected with one or more pathogens, the most common of which included respiratory viruses such as non-SARS-CoV-2 Coronaviridae, respiratory syncytial virus, enteroviruses, and rhinovirus [14].

Several studies have detected coinfections of influenza viruses among COVID-19 patients with mild to severe infections. For instance, in the early COVID-19 pandemic in Spain, Elena and colleagues reported influenza A and B coinfections among critically ill COVID-19 patients [15]. On the other hand, studies in China and Turkey reported influenza virus coinfections among patients with COVID-19 of mild to moderate severity who recovered without complications [16,17].

Despite the increasing number of reports on influenza virus coinfections among COVID-19 patients, there is limited knowledge about whether these coinfections are community- or hospital-acquired. Therefore, we performed this retrospective cohort study to investigate the prevalence of community-acquired influenza virus coinfections among COVID-19 patients in Al-Madinah, Saudi Arabia.

2. Methodology

2.1. Study design and sample collection

This was a single-center, retrospective cohort study. A total of 163 serum samples were collected from randomly selected confirmed SARS-CoV-2 patients during their visit to the emergency department at King Salman Medical City in Al-Madinah, Saudi Arabia, during the early stage of the pandemic from April to October 2020. Demographic data, including age, gender, and symptoms at the time of hospital admission, were extracted from the patients’ medical records. Serum samples were collected from the hospital’s clinical laboratory and aliquoted, then stored promptly at −20 °C for retrospective investigation. Ethical approval was obtained from the institutional review board of the General Directorate of Health Affairs in Al-Madinah (approval no. 9–2021).

2.2. Serological detection of influenza virus coinfections

Immunoglobulin M (IgM) antibodies against influenza A, influenza B, and parainfluenza-2 were screened for via indirect ELISA using Vircell IgM ELISA kits (Vircell, Granada, Spain) according to the manufacturer’s instructions. All sample wells were treated with IgG sorbent to avoid interference from rheumatoid factor and IgG antibodies. Sera and controls provided in the kits were incubated in microplates for 45 min at 37 °C. Then, wells were washed and incubated with the IgM conjugate for 30 min at 37 °C. After the second round of washing, tetramethylbenzidine (TMB) substrate was added and the plates were incubated for 20 min at room temperature, protected from light. Thereafter, the stop solution was added immediately to all wells, and the absorbance was measured at 450 nm. The antibody index values were calculated as the sample optical density value divided by the mean of the optical density values of the cutoff controls, multiplied by 10. An antibody index of >11 was considered a positive result.

3. Results

Of the 163 randomly selected confirmed SARS-CoV-2 patients in this study, approximately 4.2% showed seropositivity for influenza A and B and parainfluenza-2 (Fig. 1). IgM seropositivity for influenza A occurred in two patients (50-year-old man and 31-year-old woman). Three patients (two women and one man) showed influenza B seropositivity, all of whom were over 60 years old. Parainfluenza-2 seropositivity occurred in two male patients with age ≤40 years. The patients included 76 (55.5%) men and 61 women (44.5%) aged 22–95 years, with an average age of 50 years. As shown in Table 1, 76.6% of patients presented with fever, 34.3% with dyspnea, and 46% with cough. In addition, all patients recovered within a few days of admission without complications and were discharged from the hospital according to their medical records.
COVID-19 and influenza viruses have comparable transmission routes, including transmission via airborne droplets and direct contact (human-to-human transmission) [22], which might be affected by these control measures and lead to a decline in transmission rates and infections in the community.

Despite the similarities in the transmission routes of COVID-19 and influenza viruses and the strict control measures in New Zealand, Japan, and other countries, COVID-19 incidence did not decline as much as influenza virus incidence, and cases continue to be identified [19,20]. The differences in the duration of survival, asymptomatic transmission, and transmission dynamics of these viruses may play a role in this regard. For instance, data from many influenza seasons revealed a median primary reproduction number ($R_0$) of 1.28 [23]. In contrast, recent work conducted in the United States and some European countries found a COVID-19 $R_0$ ranging from 3.6 to 6.1 [24] that might explain the continued incidence of COVID-19 compared with influenza viruses despite the implementation of control measures.

Another speculative reason for the reduced rate of influenza virus infections during the pandemic may involve virus–virus interactions. For example, during the H1N1 pandemic in 2009, studies in Sweden and France suggested that rhinovirus circulation in the community might reduce or delay emerging influenza virus activity [25,26]. Other observations found that the increased circulation of influenza A virus in the community affected rhinovirus prevalence via an interferon-mediated mechanism [27]. Furthermore, a study in Wuhan reported on the effect of the dramatic increase in COVID-19 incidence in January 2020, which interfered with the influenza epidemic in the 2019–2020 season and resulted in a sharp decline in influenza A and B incidence that might be a reflection of virus–virus interactions [28]. This phenomenon raises the question: has COVID-19 affected influenza virus prevalence during the pandemic, and how? Further prospective studies and investigations are necessary to elucidate the possible positive and negative interspecies interactions among COVID-19, influenza, and other respiratory viruses on the scale of the individual patient and community populations.

Moreover, underestimating the circulation of respiratory viruses such as influenza during the newly emerging pandemic may have reduced the reported incidence of flu and other respiratory viruses. For instance, during the early phase of the influenza A(H1N1)pdm09 virus pandemic in Australia in 2009, Ratnamohan and colleagues reportedly misdiagnosed other clinically meaningful co-circulating respiratory agents including influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, and enteroviruses [29], a finding similar to our results in this study, wherein the detected influenza viruses were misdiagnosed during the patient’s hospitalization and only detected retrospectively. All the above-mentioned factors that are proposed to have reduced influenza infection rates during the current COVID-19 pandemic are illustrated in Fig. 2.

The present study has some limitations. This study was conducted on patients from a single center. Additionally, we could not find in the patient’s records whether they recently received influenza vaccines or not, which might influence coinfection severity. However, the study sheds light on the prevalence of community-acquired influenza virus infections among SARS-CoV-2 patients in Saudi Arabia.

5. Recommendations and concluding Remarks

In this study, we documented the low prevalence and mild co-infections of community-acquired influenza viruses (influenza A and B and para-influenza-2) among SARS-CoV-2 patients during the early phase of the COVID-19 pandemic in Al-Madinah region, Saudi Arabia.

Health service providers should take coinfections among COVID-19 patients into account, whether community-acquired or hospital-acquired, in order to prevent their progressive impact on treatment...
and management approaches. In addition, implementing broad range diagnostic tests such as respiratory panels multiplex Polymerase Chain Reaction (PCR) for COVID-19 patients would be helpful in minimizing the possibility of misdiagnosing COVID-19 coinfections as well as providing more indicators of the pathogens cycling in the community and hospitals. Prospective studies and investigations to understand co-circulating pathogens are necessary and should not be neglected during epidemics and pandemics.

Ethical approval
Written informed consent was obtained via Institutional Review Board from the General directorate of health in Madinah (Approval No.: 9–2021) for support of the use of patient information for the publication of this report.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement
STA conceived of the study, designed the experiments, and drafted the manuscript. KOA, HMM, and NAI participated intellectually in the design and framing of the manuscript. STA and NAI provided substantial intellectual direction and participated in experimental design, data analysis, and manuscript drafting. All authors read and approved the final manuscript.

Data Availability
All data and materials generated during the current study are available from the corresponding author on reasonable request.

Conflict of interest
The authors declare that they have no known competing financial interests that could have influenced the work reported in this paper.

Acknowledgments
We thank Mr. Khaled Aljabri and Mr. Adnan Khoumaeys for their help. Our thanks are also extended to the Academic Affairs in King Salman Medical City in Madinah for their support.

References
[1] Alfarouk KO, AlHoufie STS, Ahmed SBM, Shabana M, Ahmed A, Alqahtani SS, et al. Pathogenesis and management of COVID-19. J Xenobiot 2021;11:77–93. https://doi.org/10.3390/jx11020006
[2] Priyanka, Choudhary OP, Singh I, Patra G. Aerosol transmission of SARS-CoV-2: The unresolved paradox. Travel Med Infect Dis 2020:37. https://doi.org/10.1016/j.tmaid.2020.101869
[3] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3
[4] Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606. https://doi.org/10.1136/bmj.m606
[5] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061. https://doi.org/10.1001/jama.2020.1585
Ozaras R, Cirpin R, Duran A, Regamey N. The airway epithelium: soldier in the fight against respiratory viruses. Clin Microbiol Rev 2011;24:210–29. https://doi.org/10.1128/CMR.00014-10

Denney L, Ho L-PP. The role of respiratory epithelium in host defence against influenza virus infection. Biomed J 2018;41:218–33. https://doi.org/10.1016/j.bj.2018.08.004

Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome. Nat Rev Immunol 2010;10:514–26. https://doi.org/10.1038/NRRI2802

Cawcutt K, Kalil AC. Pneumonia with bacterial and viral coinfection. Curr Opin Crit Care 2017;23:385–90. https://doi.org/10.1097/MCC.0000000000000435

Alfaraj SH, Al-Tawfiq JA, Altwajri TA, Memish ZA. The impact of co-infection of influenza A virus on the severity of Middle East Respiratory Syndrome Coronavirus. J Infect 2017;74:521–3. https://doi.org/10.1016/j.jinf.2017.02.001

Wang M, Wu Q, Xu W, Qiao B, Wang J, Zheng H, et al. Clin Diagn 827 4 Samples 2018.08.004

Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, et al. Decreased Influenza Activity During the COVID-19 Pandemic — United States, Australia, Chile, and South Africa, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1305–9. https://doi.org/10.15585/mmwr.mm6937a6

Jiang C, Yao X, Zhao Y, Wu J, Huang P, Pan C, et al. Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season. Microbes Infect 2020;22:236–44. https://doi.org/10.1016/j.micinf.2020.05.005

Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Pinell E, L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC Infect Dis 2014:14. https://doi.org/10.1186/1471-2334-14-480

Ker R, Romero-Severson E, Sanchez S, Hengartner N. Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccination. J Theor Biol 2021;517:110621 https://doi.org/10.1016/j.jtbi.2021.110621

Linde A, Rötzer-Ostlund M, Zwengberg-Wirgat B, Rubino B, Brytting M. Does viral interference affect spread of influenza? Eur Surveill 2009:14.

Casalino JS, Ottmann M, Bouscambert-Duchamp M, Valette M, Morfin F, Lina B. Impact of the 2009 influenza A(H1N1) pandemic wave on the pattern of hibernation respiratory virus epidemics, France, 2009. Eur Surveill 2010:15.

Nickbakhsh S, Mail C, Mathews L, Reeve R, Johnson PCD, Thorburn F, et al. Virus-virus interactions impact the population dynamics of influenza and the common cold. Proc Natl Acad Sci USA 2019;116:27142–50. https://doi.org/10.1073/PNAS.1910831116

Zhou X, Ding G, Shu T, Tong W, Wu X, et al. The Outbreak of Coronavirus Disease 2019 Interfered with Influenza in Wuhan. SSRN Electron J 2020. https://doi.org/10.2139/SSRN.3555239

Ranatomohan VM, Taylor J, Zeng F, McPhie K, Bllytch CC, Adamson S, et al. Pandemic clinical case definitions are non-specific: multiple respiratory viruses circulating in the early phases of the 2009 influenza pandemic in New South Wales, Australia. Virol J 2014;11:113. https://doi.org/10.1186/1743-422X-11-113